Marshall Wace, LLP Acelrx Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$1.03 - $1.7 $328,942 - $542,915	-319,362 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.25 - $2.77 $399,202 - $884,632	319,362 New	319,362 $543,000
Q1 2020 May 15, 2020	SELL	$0.76 - $2.07 $139,108 - $378,888	-183,038 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.66 - $2.4 $303,843 - $439,291	183,038 New	183,038 $386,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.